Immunotherapy of metastatic disease

J. E. Talmadge, P. L. Black

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It appears that the cytokines have significant therapeutic potential as an adjunct to established therapeutic regimens. It appears that, as single agents, they will have minimal therapeutic activity. However, in minimal residual disease settings or after debulking regimens by surgery, chemotherapy, or radiotherapy, significantly increased therapeutic activity can be expected by the addition of cytokines to treatment protocols.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalSeminars in Thrombosis and Hemostasis
Volume14
Issue number1
DOIs
StatePublished - Jan 1 1988

Fingerprint

Immunotherapy
Cytokines
Residual Neoplasm
Therapeutics
Clinical Protocols
Radiotherapy
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Immunotherapy of metastatic disease. / Talmadge, J. E.; Black, P. L.

In: Seminars in Thrombosis and Hemostasis, Vol. 14, No. 1, 01.01.1988, p. 79-87.

Research output: Contribution to journalArticle

Talmadge, J. E. ; Black, P. L. / Immunotherapy of metastatic disease. In: Seminars in Thrombosis and Hemostasis. 1988 ; Vol. 14, No. 1. pp. 79-87.
@article{91d3bf6a8b1e4b1ca1ae9df81d682635,
title = "Immunotherapy of metastatic disease",
abstract = "It appears that the cytokines have significant therapeutic potential as an adjunct to established therapeutic regimens. It appears that, as single agents, they will have minimal therapeutic activity. However, in minimal residual disease settings or after debulking regimens by surgery, chemotherapy, or radiotherapy, significantly increased therapeutic activity can be expected by the addition of cytokines to treatment protocols.",
author = "Talmadge, {J. E.} and Black, {P. L.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1055/s-2007-1002759",
language = "English (US)",
volume = "14",
pages = "79--87",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Immunotherapy of metastatic disease

AU - Talmadge, J. E.

AU - Black, P. L.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - It appears that the cytokines have significant therapeutic potential as an adjunct to established therapeutic regimens. It appears that, as single agents, they will have minimal therapeutic activity. However, in minimal residual disease settings or after debulking regimens by surgery, chemotherapy, or radiotherapy, significantly increased therapeutic activity can be expected by the addition of cytokines to treatment protocols.

AB - It appears that the cytokines have significant therapeutic potential as an adjunct to established therapeutic regimens. It appears that, as single agents, they will have minimal therapeutic activity. However, in minimal residual disease settings or after debulking regimens by surgery, chemotherapy, or radiotherapy, significantly increased therapeutic activity can be expected by the addition of cytokines to treatment protocols.

UR - http://www.scopus.com/inward/record.url?scp=0023904284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023904284&partnerID=8YFLogxK

U2 - 10.1055/s-2007-1002759

DO - 10.1055/s-2007-1002759

M3 - Article

C2 - 3127885

AN - SCOPUS:0023904284

VL - 14

SP - 79

EP - 87

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 1

ER -